Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00041496 | Prevention Of Recurrence Of Atrial Fibrillation | PHASE2 | COMPLETED | 520 | — | — | Nov 1, 2001 | Dec 1, 2003 | Aug 11, 2014 | - | — |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo |
| Arm 2 | PLACEBO_COMPARATOR | Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo |
| Name | Type | Description |
|---|---|---|
| SB-207266 | DRUG | White, oval, biconvex tablets containing either 10mg, 25mg or 40mg |
| Placebo | OTHER | Placebo to match SB-207266 |
Inclusion Criteria: * Symptomatic persistent atrial fibrillation requiring DC cardioversion. * Duration of AF \>48 hrs. \<6 months Exclusion Criteria: * Concomitant Class I and/or III anti-arrhythmic drugs. * Amiodarone treatment within 3 months of the study. * Other inclusion or exclusion criter...